Who founded iOnctura?

iOnctura was founded by Catherine Pickering, Lars van der Veen.

Who are iOnctura's investors?

iOnctura's investors include Inkef, Syncona, 3B Future Health Fund, M Ventures, VI Partners, XGEN Venture, Johnson & Johnson Innovation – JJDC.

How much funding has iOnctura raised?

iOnctura has disclosed $85.8M raised across 1 of its 2 known rounds.

iOnctura

11 known investors

Find your way into iOnctura

Paths you didn't know you had: your email and LinkedIn already hold routes to the iOnctura team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer. It serves oncology patients through low-toxicity therapies aimed at extending healthspan.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Catherine Pickering Co-Founder & CEOCatherine Pickering holds a PhD in Medicinal Chemistry from the Institute of Cancer Research and an MBA from Henley Business School. Before co-founding iOnctura in 2017, she led the global oncology and immuno-oncology licensing and business development function at Merck KGaA, where she completed multiple licensing and partnership agreements.

Lars van der Veen Co-Founder & CSOLars van der Veen is a medicinal chemist with experience in pharmaceutical R&D, chemistry manufacturing and controls, and program management across small and large molecule therapies. He co-founded iOnctura, a clinical-stage oncology company developing precision oral therapeutics.

Michael Lahn CMOMichael Lahn is Chief Marketing Officer at iOnctura, a clinical-stage oncology company developing precision oral small-molecule therapies. He has background in hematology, oncology, and immunology.

Elizabeth Holt CBOElizabeth Holt held leadership roles at two acquired biotech companies—VP of Corporate Planning & Operations at Gyroscope Therapeutics (sold to Novartis for up to $1.5B in 2022) and co-founder of Aiolos Bio (acquired by GSK for $1.4B in 2024)—and previously worked as an Associate Partner at McKinsey & Company advising on healthcare strategy and M&A. She holds an MBA from NYU Stern, an MSc from the London School of Economics, and a BA from Davidson College.

Steven SciutoCFO

Michelle Tsai COOShe previously held marketing and commercial leadership roles at Novartis Oncology, including directing global launch marketing teams for breast cancer and melanoma treatments, and spent over a decade in oncology brand marketing with P&L responsibility.

Investors · 11

Inkef✓ confirmed by iOncturaAmsterdam

How we know: the company's own site · Inkef's portfolio page · a partner's Signal profile · funding news · prnewswire.com · the VCSheet dataset · Not right? Tell us

Syncona✓ confirmed by iOncturaLondon

How we know: Syncona's portfolio page · the company's own site · a partner's Signal profile · funding news · globalgenes.org · open dataset · 5k.vc investor directory · Not right? Tell us

3B Future Health Fundlisted by 3B Future Health FundMonaco · $12M

How we know: 3B Future Health Fund's portfolio page · funding news · clinicaltrialsarena.com · open dataset · 5k.vc investor directory · Not right? Tell us

M Ventureslisted by M VenturesAmsterdam · $10.8M

How we know: a partner's Signal profile · prnewswire.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

VI Partnerslisted by VI PartnersAltendorf · $2.2M – $4.5M

How we know: VI Partners's portfolio page · prnewswire.com · Not right? Tell us

XGEN Venturelisted by XGEN VentureMilan

Johnson & Johnson Innovation – JJDCreportedNew Brunswick

How we know: a partner's Signal profile · Not right? Tell us

Also in the syndicate · 4

EIC FundMerck VenturesSchroder AdveqSchroders Capital

Funding

SEC filings, press & company announcements

$85.8M disclosed across 1 of 2 rounds · 2020–2024

$85.8MSeries BJun 2024 · 2 sources
Syncona (lead), 3B Future Health Fund, EIC Fund, Inkef Capital, M Ventures, Merck Ventures, Schroders Capital, VI Partners
Source ↗
Undisclosed amountSeries AJan 2020 · 2 sources
INKEF Capital (lead), VI Partners (lead), M Ventures, Schroder Adveq
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

4 people who came through iOnctura went on to found or lead other companies.

Mark VellecaBoard ChairFounded Stridebio +1 Keno GutierrezBoard MemberFounded Brandaris Therapeutics Elizabeth HoltCBOFounded Aiolos Bio JOANNA HOROBINNon Executive Chair of the Board of DirectorsFounded Syndax Pharmaceuticals

In the news

iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Developmentprnewswire.com · Jan 2020

Frequently asked questions

What does iOnctura do?: iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer. It serves oncology patients through low-toxicity therapies aimed at extending healthspan.
Who founded iOnctura?: iOnctura was founded by Catherine Pickering, Lars van der Veen.
Who are iOnctura's investors?: iOnctura's investors include Inkef, Syncona, 3B Future Health Fund, M Ventures, VI Partners, XGEN Venture, Johnson & Johnson Innovation – JJDC.
How much funding has iOnctura raised?: iOnctura has disclosed $85.8M raised across 1 of its 2 known rounds.